T
Thomas Hugh Jones
Researcher at Barnsley Hospital NHS Foundation Trust
Publications - 4
Citations - 145
Thomas Hugh Jones is an academic researcher from Barnsley Hospital NHS Foundation Trust. The author has contributed to research in topics: Blood sampling & Sexual function. The author has an hindex of 3, co-authored 4 publications receiving 111 citations.
Papers
More filters
Journal ArticleDOI
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Frans M.J. Debruyne,Hermann M. Behre,Claus G. Roehrborn,Mario Maggi,Frederick C. W. Wu,Fritz H. Schröder,Thomas Hugh Jones,Hartmut Porst,Geoffrey Hackett,Olivia A. Wheaton,Antonio Martin-Morales,Eric J.H. Meuleman,Glenn R. Cunningham,Hozefa A. Divan,Raymond C. Rosen +14 more
TL;DR: To evaluate the effects of testosterone‐replacement therapy (TRT) on prostate health indicators in hypogonadal men, including rates of prostate cancer diagnoses, changes in prostate‐specific antigen (PSA) levels and lower urinary tract symptoms (LUTS) over time.
Journal ArticleDOI
Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).
Mario Maggi,Frederick C. W. Wu,Thomas Hugh Jones,Graham Jackson,Hermann M. Behre,Geoffrey Hackett,Antonio Martin-Morales,Giancarlo Balercia,Adrian S. Dobs,Stefan Arver,Marcello Maggio,Glenn R. Cunningham,Andrea M. Isidori,Richard Quinton,Olivia A. Wheaton,Flora S. Siami,Raymond C. Rosen +16 more
TL;DR: The aim of this study was to assess cardiovascular (CV) safety of testosterone replacement therapy (TRT) in a large, diverse cohort of European men with hypogonadism (HG).
Journal ArticleDOI
Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Raymond C. Rosen,Frederick C. W. Wu,Hermann M. Behre,Hartmut Porst,Eric J. H. Meuleman,Mario Maggi,Javier Romero-Otero,Juan Ignacio Martínez-Salamanca,Thomas Hugh Jones,Frans M.J. Debruyne,Karl-Heinz Kurth,Geoff Hackett,Richard Quinton,Peter Ströberg,Yacov Reisman,Edoardo S. Pescatori,Antonio Martin Morales,Lluís Bassas,Natalio Cruz,Glenn R. Cunningham,Olivia A. Wheaton +20 more
TL;DR: T-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment, confirming the broad and sustained benefits of TRT across major QOL dimensions, including sexual, somatic, and psychological health.
Journal ArticleDOI
The impact of testosterone level on body composition in men with type 2 diabetes (T2D)
TL;DR: The impact of testosterone level on body composition in men with type 2 diabetes (T2D) and the role of serum testosterone levels in body composition is studied.